BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Policy

  IONIS-HTT Rx (RG6042) Granted PRIME Designation by the European Medicines Agency for the Treatment of People with Huntington’s Disease

  IONIS-HTT Rx is the first and only drug to demonstrate reduction of mutant huntingtin protein, the underlying cause of Huntington’s disease, in patients

  August 2, 2018

   · 

  6 min read
• Business

  Aratana Therapeutics Reports Second Quarter 2018 Financial Results

  Aratana Therapeutics, Inc. announced its second quarter 2018 financial results.

  August 2, 2018

   · 

  20 min read
• Business

  Medifast, Inc. Announces Second Quarter 2018 Financial Results

  Second Quarter Revenue Increased 55% and EPS Increased 84%

  August 2, 2018

   · 

  25 min read
• Deals

  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on July 31, 2018

  Akebia Therapeutics, Inc. granted eight newly-hired employees options to purchase an aggregate of 37,400 shares of Akebia’s common stock on July 31, 2018, as inducements material to each such employee’s entering into employment with Akebia.

  August 2, 2018

   · 

  1 min read
• Business

  BioTime Reports 2018 Second Quarter Results and Recent Corporate Accomplishments

  BioTime to receive $43 million from Juvenescence

  August 2, 2018

   · 

  25 min read
• Business

  Cerus Corporation Reports Second Quarter 2018 Results

  Product revenue increases 62% compared to 2017

  August 2, 2018

   · 

  13 min read
• Business

  Nevro Reports Second Quarter 2018 Financial Results

  Nevro Corp. reported financial results for the three and six months ended June 30, 2018.

  August 2, 2018

   · 

  12 min read
• Business

  IAVI and the Public Health Agency of Canada Enter into License Agreement for Technology to Enable Lassa Fever Vaccine Development

  IAVI to Apply Expertise in Viral Vector Vaccines to Lassa Fever Prevention Effort

  August 2, 2018

   · 

  6 min read
• Business

  Healthcare Trust of America, Inc. Announces Greenville, SC Medical Office Sale Agreement

  The portfolio consists of 16 MOBs totaling approximately 856,000 square feet of GLA located in Greenville, SC.

  August 2, 2018

   · 

  5 min read
• BioMidwest

  AllerPops Inventor Presents Study Linking Prebiotics to Allergy Relief at Aspen Allergy Conference

  Prebiotics may be the answer to permanent, drug-free allergy relief.

  August 2, 2018

   · 

  3 min read